Oncotarget

Reviews:

Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

Yi Cai, Sonam Dodhia and Gloria H. Su _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:22203-22217. https://doi.org/10.18632/oncotarget.14729

Metrics: PDF 2585 views  |   HTML 3747 views  |   ?  


Abstract

Yi Cai1, Sonam Dodhia1 and Gloria H. Su1,2,3

1 Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York, NY, USA

2 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA

3 Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA

Correspondence to:

Gloria H. Su, email:

Keywords: PI3K signaling, head and neck squamous cell carcinoma, PIK3CA mutation, PI3K inhibitor, personalized medicine

Received: October 15, 2016 Accepted: January 09, 2017 Published: January 18, 2017

Abstract

The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14729